InflaRx Yönetim

Yönetim kriter kontrolleri 2/4

InflaRx CEO'su Niels Riedemann, Jan2007 tarihinde atandı, in görev süresi 17.83 yıldır. şirketin hisselerinin 1.82% doğrudan sahiptir ve bu hisselerin değeri $ 1.64M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.9 yıl ve 5.5 yıldır.

Anahtar bilgiler

Niels Riedemann

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresi17.8yrs
CEO sahipliği1.8%
Yönetim ortalama görev süresi3.9yrs
Yönetim Kurulu ortalama görev süresi5.5yrs

Son yönetim güncellemeleri

Recent updates

InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely

Jun 25
InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Dec 23
We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Aug 17
InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Mar 28
We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?

Nov 30
Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?

InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients

Sep 29

InflaRx reports Q2 results

Aug 05

InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients

Jul 26

Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

Jul 16
Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

Jul 06

InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy

Jun 29

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Apr 01
Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Our First Look At InflaRx

Dec 29

Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)

Dec 15
Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Aug 27
InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks

Aug 25

InflaRx initiates mid-stage vilobelimab skin cancer trial

Jun 08

We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth

May 01
We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth

Do Institutions Own InflaRx N.V. (NASDAQ:IFRX) Shares?

Mar 02
Do Institutions Own InflaRx N.V. (NASDAQ:IFRX) Shares?

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Jan 08
We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx concludes enrollment in vilobelimab study in blood vessel inflammation disorder

Jan 05

InflaRx reports Q3 results

Oct 29

CEO

Niels Riedemann (51 yo)

17.8yrs

Görev süresi

Prof. Dr. Niels C. Riedemann, M.D. is Chief Executive Officer of InflaRx N.V. since 2007 and serves as its Executive Director. Dr. Riedemann founded InflaRx N.V. in 2007 as InflaRx GmbH. Dr. Riedemann spen...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Niels Riedemann
Co-Founder17.8yrsVeri yok1.82%
$ 1.6m
Renfeng Guo
Co-Founder17.8yrsVeri yok2.99%
$ 2.7m
Thomas Taapken
Chief Financial Officer4.1yrsVeri yok0.0059%
$ 5.4k
Derval O'Carroll
Senior VP and Global Head of Regulatory Affairs & Compliance1.6yrsVeri yokVeri yok
Camilla Chong
Chief Medical Officer1.3yrsVeri yokVeri yok
Jan Medina
Head of Investor Relations & VPless than a yearVeri yokVeri yok
Christian Schmid
VP and Head of Legal Affairs & General Counselno dataVeri yokVeri yok
Nicole Bertsch
Senior Director & Head of Human Resources3.7yrsVeri yokVeri yok
Maria Habel
VP, Head of Preclinical R&D and QC11.8yrsVeri yokVeri yok
Bruce Burnett
VP & Head of Medical Affairsno dataVeri yokVeri yok
Kofi Boaten
Senior Director and Head of Supply Quality & Clinical Trial Suppliesno dataVeri yokVeri yok
Peter Hurt
Senior Director and Head of Drug Safety & Pharmacovigilianceno dataVeri yokVeri yok

3.9yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: IFRX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.9 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Niels Riedemann
Co-Founderno dataVeri yok1.82%
$ 1.6m
Renfeng Guo
Co-Founderno dataVeri yok2.99%
$ 2.7m
Nicolas Fulpius
Independent Chairman of the Board17.8yrsVeri yok0.79%
$ 715.9k
K. Reinhart
Member of Scientific Advisory Boardno dataVeri yokVeri yok
P. Ward
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Richard Brudnick
Independent Non-Executive Director5.5yrsVeri yok0.085%
$ 76.5k
Hege Hellstrom
Non-Executive Director1.6yrsVeri yokVeri yok
Mark Kubler
Independent Non-Executive Director9.8yrsVeri yok1.63%
$ 1.5m
Anthony Gibney
Independent Non-Executive Director3.5yrsVeri yok0.017%
$ 15.3k

5.5yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IFRX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).